Vernal keratoconjunctivitis

Eye

Volumn 18, Issue 4, 2004, Pages 345-351

  Bonini, S ^a,b   Coassin, M ^a   Aronni, S ^a   Lambiase, A ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Allergic conjunctivitis; Pathogenesis; Treatment; Vernalkeratoconjunctivitis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CASTOR OIL; CROMOGLYCATE DISODIUM; CYCLOSPORIN A; ESTROGEN RECEPTOR; IMMUNOGLOBULIN E; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; LODOXAMIDE TROMETAMOL; MONTELUKAST; NEDOCROMIL SODIUM; NERVE GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OLIVE OIL; PROGESTERONE RECEPTOR; SEX HORMONE; SPAGLUMIC ACID; STEROID; SUBSTANCE P; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ANAMNESIS; BURNING SENSATION; CATARACT; CELL DIFFERENTIATION; CELL INFILTRATION; CONJUNCTIVAL HYPEREMIA; CORNEA INJURY; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG FORMULATION; EOSINOPHIL; FAMILY HISTORY; GENE OVEREXPRESSION; GLAUCOMA; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; KERATITIS; LACRIMATION; LYMPHOCYTE ACTIVATION; MAST CELL; OUTCOMES RESEARCH; PHOTOPHOBIA; PROGNOSIS; PRURITUS; REVIEW; SKIN TEST; SYMPTOMATOLOGY; TH2 CELL; TREATMENT PLANNING; VERNAL CONJUNCTIVITIS;

EID: 2342502675     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.eye.6700675     Document Type: Review

References (69)

1. Beigelman MN. Vernal Conjunctivitis. University of Southern California Press: Los Angeles, 1950.
2. Donshik PC, Ehlers WH. Clinical immunologic diseases. In: Srolin G, Thoft RA (eds). The Cornea, 3rd ed, chap. 12. Little, Brown & Company: Boston, 1994.
3. Brody JM, Foster CS. Vernal conjunctivitis. In: Pepose JS, Holland GN, Wilhelmus KR (eds). Ocular Infection and Immunity, Chap. 27. Mosby: St Louis, 1996.
4. Coombs RRA, Gell PGH. The classification of allergic reactions underlying disease. In: Gell PGH, Coombs RRA (eds). Clinical Aspects of Immunology. Chap. 13. Blackwell Scientific Publications: Oxford, 1962.
5. Bonini S, Bonini S, Lambiase A, Marchi S, Pasqualetti P, Zuccaro O et al. Vernal keratoconjunctivitis revisited: a case series of 195 patients with long-term followup. Ophthalmology 2000; 107: 1157-1163.
6. Bonini S, Bonini S, Schiavone M, Centofanti M, Allansmith MR, Bucci MG. Conjunctival hyperresponsiveness to ocular histamine challenge in patients with vernal conjunctivitis. J Allergy Clin Immunol 1992; 89: 103-107.
7. Togias AG, Naclerio RM, Proud D, Fish JE, Adkinson Jr NF, Kagey-Sobotka A et al. Nasal challenge with cold, dry air results in release of inflammatory mediators. Possible mast cell involvement. J Clin Invest 1985; 76: 1375-1381.
8. Cameron JA. Shield ulcers and plaques of the cornea in vernal keratoconjunctivitis. Ophthalmology 1995; 102: 985-993.
9. Tabbara KF. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol 1999; 34: 88-92.
10. Ballow M, Mendelson L. Specific immunoglobulin E antibodies in tear secretions of patients with vernal conjunctivitis. J Allergy Clin Immunol 1980; 66: 112-118.
11. Easty DL, Birkenshaw M, Merrett T, Merrett J, Entwhistle C, Amer B. Immunological investigations in vernal eye disease. Trans Ophthalmol Soc U K 1980; 100: 98-107.
12. Abelson MB, Schaefer K. Conjunctivitis of allergic origin: immunologic mechanisms and current approaches to therapy. Surv Ophthalmol 1993; 38: 115-132.
13. Montan PG, van Hage-Hamsten M. Eosinophil cationic protein in tears in allergic conjunctivitis. Br J Ophthalmol 1996; 80: 556-560.
14. Aalders-Deenstra V, Kok PT, Bruynzeel PL. Measurement of total IgE antibody levels in lacrimal fluid of patients suffering from atopic and non-atopic eye disorders. Evidence for local IgE production in atopic eye disorders? Br J Ophthalmol 1985; 69: 380-384.
15. Bonini S, Lambiase A, Juhas T, Bonini S. Allergic conjunctivitis. Dev Ophthalmol 1999; 30: 54-61.
16. Bonini S, Bonini S, Bucci MG, Berruto A, Adriani E, Balsano F et al. Allergen dose response and late symptoms in a human model of ocular allergy. J Allergy Clin Immunol 1990; 86: 869-876.
17. Bonini S, Tomassini M, Adriani E, Magrini L, Rumi C, Bussa S et al. Markers of eosinophilic inflammation in allergic diseases. Allergy 1993; 48: 133-137; discussion 143-145.
18. Trocme SD, Aldave AJ. The eye and the eosinophil. Surv Ophthalmol 1994; 39: 241-52.
19. Fujishima H, Shimazaki J, Takeuchi T, Saito I, Tsubota K. Interleukin-4 and IgE in seasonal allergic conjunctivitis. Ophthalmologica 1996; 210: 325-328.
20. Bielory L, Frohman LP. Allergic and immunologic disorders of the eye. J Allergy Clin Immunol 1992; 89: 1-15.
21. Bonini S, Bonini S. IgE and non-IgE mechanisms in ocular allergy. Ann Allergy 1993; 71: 296-299.
22. Bonini S, Bonini S, Lambiase A, Magrini L, Rumi C, Del Prete G et al. Vernal keratoconjunctivitis: a model of 5q cytokine gene cluster disease. Int Arch Allergy Immunol 1995; 107: 95-98.
23. Maggi E, Biswas P, Del Prete G, Parronchi P, Macchia D, Simonelli C et al. Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol 1991; 146: 1169-1174.
24. van Leeuwen BH, Martinson ME, Webb GC, Young IG. Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood 1989; 73: 1142-1148.
25. Metz DP, Bacon AS, Holgate S, Lightman SL. Phenotypic characterization of T cells infiltrating the conjunctiva in chronic allergic eye disease. J Allergy Clin Immunol 1996; 98: 686-696.
26. Bagnasco M, Pesce G, Fiorino N, Riccio AM, Ciprandi G, Buscaglia S et al. In situ hybridization analysis of ICAM-1 (CD54) mRNA on conjunctival epithelium during allergic inflammation. Clin Exp Allergy 1997; 27: 737-743.
27. Tomassini M, Magrini L, De Petrillo G, Adriani E, Bonini S, Balsano F et al. Serum levels of eosinophil cationic protein in allergic diseases and natural allergen exposure. J Allergy Clin Immunol 1996; 97: 1350-1355.
28. Gill KS, Yannariello-Brown J, Patel J, Nakajima N, Rajaraman S, Trocme SD. ICAM-1 expression in corneal epithelium of a patient with vernal keratoconjunctivitis: case report. Cornea 1997; 16: 107-111.
29. Baraniuk JN. Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997; 99: S763-S772.
30. Wardlaw AJ, Hay H, Cromwell O, Collins JV, Kay AB. Leukotrienes, LTC4 and LTB4, in bronchoalveolar lavage in bronchial asthma and other respiratory diseases. J Allergy Clin Immunol 1989; 84: 19-26.
31. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197-206.
32. Creticos PS, Peters SP, Adkinson Jr NF, Naclerio RM, Hayes EC, Norman PS et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984; 310: 1626-1630.
33. Bisgaard H, Olsson P, Bende M. Effect of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance and nasal secretion in humans. Clin Allergy 1986; 16: 289-297.
34. Knapp HR. Reduced allergen-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990; 323: 1745-1748.
35. Marom Z, Shelhamer JH, Kaliner M. Effects of arachidonic acid, monohydroxyeicosatetraenoic acid and prostaglandins on the release of mucous glycoproteins from human airways in vitro. J Clin Invest 1981; 67: 1695-1702.
36. Reiss TF, Altman LC, Chervinsky P, Bewtra A, Stricker WE, Noonan GP et al. Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist, in patients with chronic asthma. J Allergy Clin Immunol 1996; 98: 528-534.
37. Orning L, Kaijser L, Hammarstrom S. In vivo metabolism of leukotriene C4 in man: urinary excretion of leukotriene E4. Biochem Biophys Res Commun 1985; 130: 214-220.
38. Nathan H, Naveh N, Meyer E. Levels of prostaglandin E2 and leukotriene B4 in tears of vernal conjunctivitis patients during a therapeutic trial with indomethacin. Doc Ophthalmol 1994; 85: 247-257.
39. Kulkarni PS, Srinivason BD. Synthesis of slow reacting substance-like activity in rabbit conjunctiva and anterior uvea. Invest Ophthalmol Vis Sci 1983; 24: 1079-1085.
40. Sengor T, Irkec M, Gulen Y, Taseli M, Erker H. Tear LTC4 levels in patients with subclinical contact lens related giant papillary conjunctivitis. CLAO J 1995; 21: 159-162.
41. Proud D, Sweet J, Stein P, Settipane RA, Kagey-Sobotka A, Friedlaender MH et al. Inflammatory mediator release on conjunctival provocation of allergic subjects with allergen. J Allergy Clin Immunol 1990; 85: 896-905.
42. Bisgaard H, Ford-Hutchinson AW, Charleson S, Taudorf E. Detection of leukotriene C4-liked immunoreactivity in tear fluid from subjects challenged with specific allergen. Prostaglandins 1984; 27: 369-374.
43. Bisgaard H, Ford-Hutchinson AW, Charleson S, Taudorf E. Production of leukotrienes in human skin and conjunctival mucosa after specific allergen challenge. Allergy 1985; 40: 417-423.
44. Spada CS, Woodward DF, Hawley SB, Nieves AL. Leukotrienes cause eosinophil emigration into conjunctival tissue. Prostaglandins 1986; 31: 795-809.
45. Woodward DF, Ledgard SE. Effect of LTD4 on conjunctival vasopermeability and blood-aqueous barrier integrity. Invest Ophthalmol Vis Sci 1985; 26: 481-485.
46. Lambiase A, Bonini S, Micera A, Tirassa P, Magrini L, Bonini S et al. Increased plasma levels of substance P in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci 1997; 38: 2161-2164.
47. Fujishima H, Takeyama M, Takeuchi T, Saito I, Tsubota K. Elevated levels of substance P in tears of patients with allergic conjunctivitis and vernal keratoconjunctivitis. Clin Exp Allergy 1997; 27: 372-378.
48. Lambiase A, Bonini S, Bonini S, Micera A, Magrini L, Bracci-Laudiero L et al. Increased plasma levels of nerve growth factor in vernal keratoconjunctivitis and relationship to conjunctival mast cells. Invest Ophthalmol Vis Sci 1995; 36: 2127-2132.
49. Bonini S, Lambiase A, Bonini S, Angelucci F, Magrini L, Manni L et al. Circulating nerve growth factor levels are increased in humans with allergic diseases and asthma. Proc Natl Acad Sci USA 1996; 93: 10955-10960.
50. Kramer P, Lubkin V, Potter W, Jacobs M, Labay G, Silverman P. Cyclic changes in conjunctival smears from menstruating females. Ophthalmology 1990; 97: 303-307.
51. Bonini S, Lambiase A, Schiavone M, Centofanti M, Palma LA, Bonini S. Estrogen and progesterone receptors in vernal keratoconjunctivitis. Ophthalmology 1995; 102: 1374-1379.
52. Tchernitchin A, Roorijck J, Tchernitchin X, Vandenhende J, Galand F. Dramatic early increase in uterine eosinophils after oestrogen administration. Nature 1974; 248: 142-143.
53. Grunert G, Porcia M, Neumann G, Sepulveda S, Tchernitchin AN. Progesterone interaction with eosinophils and with responses already induced by oestrogen in the uterus. J Endocrinol 1984; 102: 295-303.
54. Bonini S, Schiavone M, Bonini S, Magrini L, Lischetti P, Lambiase A et al. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis. Ophthalmology 1997; 104: 849-853.
55. D'Angelo G, Lambiase A, Cortes M, Sgrulletta R, Pasqualetti R, Lamagna A et al. Preservative-free diclofenac sodium 0.1% for vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 2003; 241: 192-195.
56. Secchi AG, Tognon MS, Leonardi A. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol 1990; 110: 641-645.
57. BenEzra D, Matamoros N, Cohen E. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc 1988; 20: 644-649.
58. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002; 89: 298-303.
59. Bielory L, Bonini S, Bonini S. Allergic eye disorders. Clin Allergy Immunol 2002; 16: 311-323.
60. Leonardi A, Borghesan F, DePaoli M, Plebani M, Secchi AG. Procollagens and inflammatory cytokine concentrations in tarsal and limbal vernal keratoconjunctivitis. Exp Eye Res 1998; 67: 105-112.
61. Allansmith MR. The Eye in Immunology. St Louis: Mosby, 1980.
62. Abelson MB, Butrus SI, Weston JH. Aspirin therapy in vernal conjunctivitis. Am J Ophthalmol 1983; 95: 502-505.
63. Chaudhary KP. Evaluation of combined systemic aspirin and cromolyn sodium in intractable vernal catarrh. Ann Ophthalmol 1990; 22: 314-318.
64. Lambiase A, Bonini St, Rasi G, Coassin M, Bruscolini A, Bonini Se. Montelukast, a leukotriene receptor antagonist, in vernal keratoconjunctivitis associated with asthma. Arch Ophthalmol 2003; 121: 615-620.
65. Neumann E, Gutmann MJ, Blumenkrantz N, Michaelson IC. A review of 400 cases of vernal conjunctivitis. Am J Ophthalmol 1959; 47: 166-172.
66. Cameron JA. Shied ulcers and plaques of the cornea in vernal keratoconjunctivitis. Ophthalmology 1995; 102: 985-993.
67. Abu El-Asrar AM, Geboes K, Missotten L, Emarah MH, Maudgal PC, Desmet V. Cytological and immunohistochemical study of the limbal form of vernal keratoconjunctivitis by the replica technique. Br J Ophthalmol 1987; 71: 867-872.
68. Abu el-Asrar AM, Van den Oord JJ, Geboes K, Missotten L, Emarah MH, Desmet V. Immunopathological study of vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol 1989; 227: 374-379.
69. Leonardi A, DeFranchis G, Zancanaro F, Crivellari G, De Paoli M, Plebani M et al. Identification of local Th2 and Th0 lymphocytes in vernal conjunctivitis by cytokine flow cytometry. Invest Ophthalmol Vis Sci 1999; 40: 3036-3040.